Insider Transactions
| Date | Name | Title | Filing | Type | Shares Traded | Price Range | Total Held |
|---|---|---|---|---|---|---|---|
| Nov 30, 2022 |
Director
|
Director | Form 4 | Open market or private purchase of non-derivative or derivative security | 50,000 | $0.45 | 270,244 |
| Oct 27, 2022 |
Director
|
Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 50,000 | $0.43 | 220,244 |
| Aug 31, 2022 |
Director
|
Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 25,000 | -- | 67,660 |
| Aug 31, 2022 |
Director
|
Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 75,000 | -- | 75,000 |
| Aug 31, 2022 |
Director
|
Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 27,380 | -- | 27,380 |
| Aug 31, 2022 |
Director
|
Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 86,301 | -- | 86,301 |
| Aug 31, 2022 |
Director
|
Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 25,000 | -- | 54,066 |
| Aug 31, 2022 |
Director
|
Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 75,000 | -- | 75,000 |
| Aug 31, 2022 |
Director
|
Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 25,000 | -- | 29,759 |
| Aug 31, 2022 |
Director
|
Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 75,000 | -- | 75,000 |
| Aug 31, 2022 |
Director
|
Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 25,000 | -- | 195,244 |
| Aug 31, 2022 |
Director
|
Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 75,000 | -- | 75,000 |
| Jun 23, 2022 |
Chief Medical Officer
|
Chief Medical Officer | Form 4 | Open market or private sale of non-derivative or derivative security | 6,667 | $0.84 | 644,790 |
| Jun 23, 2022 |
Chief Medical Officer
|
Chief Medical Officer | Form 4 | Other acquisition or disposition | -- | -- | 7,226 |
| Jun 23, 2022 |
Chief Legal Officer
|
Chief Legal Officer | Form 4 | Other acquisition or disposition | -- | -- | 6,250 |
| Jun 23, 2022 |
Director, CEO & President
|
Director, CEO & President | Form 4 | Other acquisition or disposition | -- | -- | 14,139 |
| Jun 22, 2022 |
Chief Medical Officer
|
Chief Medical Officer | Form 4 | Open market or private sale of non-derivative or derivative security | 6,096 | $0.81 | 651,457 |
| Jun 21, 2022 |
Director
|
Director | Form 4 | Open market or private sale of non-derivative or derivative security | 4,283 | $0.79 | 42,660 |
| Jun 21, 2022 |
EVP & CFO
|
EVP & CFO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 334,507 | -- | 363,784 |
| Jun 21, 2022 |
EVP & CFO
|
EVP & CFO | Form 4 | Open market or private sale of non-derivative or derivative security | 3,569 | $0.79 | 360,215 |
| Jun 21, 2022 |
EVP & CFO
|
EVP & CFO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 1,515,957 | -- | 1,515,957 |
| Jun 21, 2022 |
Director
|
Director | Form 4 | Open market or private sale of non-derivative or derivative security | 5,711 | $0.79 | 29,066 |
| Jun 21, 2022 |
Chief Medical Officer
|
Chief Medical Officer | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 405,040 | -- | 657,553 |
| Jun 21, 2022 |
Chief Medical Officer
|
Chief Medical Officer | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 1,488,940 | -- | 1,488,940 |
| Jun 21, 2022 |
Chief Legal Officer
|
Chief Legal Officer | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 246,085 | -- | 491,025 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.